环戊君 | 52109-93-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 环戊君
• 英文名称: <1-Hydroxy-cyclopentyl>-phenyl-essigsaeure-<2-diaethylamino-aethylester>
• 英文别名: (1-hydroxy-cyclopentyl)-phenyl-acetic acid-(2-diethylamino-ethyl ester)；(1-Hydroxy-cyclopentyl)-phenyl-essigsaeure-(2-diaethylamino-aethylester)；Cyclodrine；2-(diethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate
• CAS: 52109-93-0
• 化学式: C₁₉H₂₉NO₃
• 分子量: 319.444
• InChiKey: LMKPHJYTFHAGHK-UHFFFAOYSA-N

物化性质

• 沸点：
  436.1±20.0 °C(Predicted)
• 密度：
  1.103±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  23
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2922509090

反应信息

• 作为产物：
  描述：

  N,N-二乙基氯乙胺 、 alkaline earth salt of/the/ methylsulfuric acid 生成 环戊君
  参考文献：
  名称：

  Antispasmodics. Esters of β-Alkyltropic Acids

  摘要：

  DOI：

  10.1021/ja01153a053

文献信息

• [EN] FARNESOID X RECEPTOR AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DU RÉCEPTEUR X FARNÉSOÏDE ET LEURS UTILISATIONS
  申请人：METACRINE INC

  公开号：WO2017049177A1

  公开（公告）日：2017-03-23

  Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

  本发明涉及法尼醇X受体激动剂化合物，制造此类化合物的方法，包含此类化合物的药物组合物和药品，以及使用此类化合物治疗与法尼醇X受体活性相关的状况、疾病或失调的方法。
• [EN] THIENOPYRROLE COMPOUNDS AND USES THEREOF AS INHIBITORS OF OPLOPHORUS-DERIVED LUCIFERASES<br/>[FR] COMPOSÉS DE THIÉNOPYRROLE ET LEURS UTILISATIONS À TITRE D'INHIBITEURS DE LUCIFÉRASES DÉRIVÉES D'OPLOPHORUS
  申请人：PROMEGA CORP

  公开号：WO2016210294A1

  公开（公告）日：2016-12-29

  Thienopyrrole compounds that may inhibit Oplophorus -derived luciferases are disclosed, as well as compositions and kits comprising the thienopyrrole compounds, and methods of using the thienopyrrole compounds.

  披露了可能抑制Oplophorus衍生的荧光素酶的噻吩并吡咯化合物，以及包含这些噻吩并吡咯化合物的组合物和试剂盒，以及使用这些噻吩并吡咯化合物的方法。
• [EN] NOVEL OXADIAZOLE COMPOUNDS<br/>[FR] COMPOSÉS INÉDITS D'OXADIAZOLE
  申请人：ABBOTT LAB

  公开号：WO2011071570A1

  公开（公告）日：2011-06-16

  Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed.

  新型噁二唑化合物，含有这种化合物的药物组合物以及将这些化合物或组合物用作治疗与调节S1P家族G蛋白偶联受体活性相关的疾病的激动剂或拮抗剂的用途被披露，特别是通过提供有益的免疫抑制作用。
• Hydroxylated nebivolol metabolites
  申请人：O'Donnell P. John

  公开号：US20070014733A1

  公开（公告）日：2007-01-18

  Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  羟基化奈必洛尔代谢物在急性给药后以浓度依赖性方式增加人内皮细胞制剂的一氧化氮释放。此外，羟基化奈必洛尔代谢物，包括但不限于4-羟基-6,6'-二氟代-、4-羟基-5-苯酚-6,6'-二氟代-和4-羟基-8-苯并-6,6'-二氟代-，在慢性给药后能够增加人内皮细胞的一氧化氮释放能力。本发明提供了羟基化奈必洛尔代谢物和包含奈必洛尔和/或至少一种羟基化奈必洛尔代谢物和/或至少一种用于治疗心血管疾病的附加化合物的组合物，以及可药用的盐。此外，本发明还提供了通过给药至少一种能够释放治疗有效量的一氧化氮到受血管疾病影响的靶向部位的羟基化奈必洛尔代谢物来治疗和/或预防血管疾病的方法。本发明还涉及通过给药至少一种羟基化奈必洛尔代谢物来治疗和/或预防偏头痛。本发明还可以与治疗代谢综合征障碍的其他治疗联合使用，或作为单一治疗。
• [EN] TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE TYROSINE KINASES
  申请人：PRINCIPIA BIOPHARMA INC

  公开号：WO2012158764A1

  公开（公告）日：2012-11-22

  The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.

  本公开提供了一些酪氨酸激酶抑制剂及其药用盐，特别是BLK、BMX、EGFR、HER2、HER4、ITK、TEC、BTK和TXK，因此适用于治疗通过抑制酪氨酸激酶可治疗的疾病，如癌症和炎症性疾病（如关节炎等）。还提供了含有这些化合物和药用盐的药物组合物，以及制备这些化合物和药用盐的方法。